Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.36 |
| ▸ | WNT3A | P56704 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10212389 | 0.80 | NEK2 (0.52) | ROCK2ROCK1CTNNB1WNT3ANPC1 | |
| Nitrous Acid SCHEMBL13276537 | 0.79 | ROCK2 (0.37) | ROCK2ROCK1CTNNB1WNT3ANPC1 | |
| Nitrous Acid SCHEMBL13276538 | 0.79 | ROCK2 (0.37) | ROCK2ROCK1CTNNB1WNT3ANPC1 | |
| SCHEMBL182744 | 0.78 | NEK2 (0.47) | ROCK2ROCK1CTNNB1WNT3ANPC1 | |
| SCHEMBL182745 | 0.78 | NEK2 (0.47) | ROCK2ROCK1CTNNB1WNT3ANPC1 | |
| SCHEMBL10212410 | 0.77 | ADORA2A (0.34) | — | |
| SCHEMBL182453 | 0.72 | CHEK1 (0.44) | ROCK2ROCK1RAB9ATRPA1FGFR1 | |
| SCHEMBL27604934 | 0.66 | ROCK2 (0.43) | ROCK2ROCK1CTNNB1WNT3ANPC1 | |
| SCHEMBL15651326 | 0.66 | CHEK1 (0.44) | ROCK2ROCK1CTNNB1WNT3ARAB9A | |
| SCHEMBL14738406 | 0.66 | CHEK1 (0.56) | ROCK2ROCK1RAB9ATRPA1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422263-B2 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9073939-B2 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8642595-B2 | Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172221-A1 | ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | MET, ERBB4, RET | ROCK2 1431/4885ROCK1 1240/4885CTNNB1 2666/4885 |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | MET, RET, ERBB2 | ROCK2 1569/4885ROCK1 1373/4885CTNNB1 1638/4885 |
| US-20120264785-A1 | Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof | MET, DCK, RET | ROCK2 971/4885ROCK1 844/4885CTNNB1 2755/4885 |
| US-20120190709-A1 | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof | BMX, MET, ABL1 | ROCK2 1054/4885ROCK1 1108/4885CTNNB1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.